Ratnakar Securities Pvt. Ltd.

WINDLAS BIOTECH LTD.

NSE : WINDLASBSE : 543329ISIN CODE : INE0H5O01029Industry : Pharmaceuticals & DrugsHouse : Private

BSE770.65-20.3 (-2.57 %)

PREV CLOSE ( ) 790.95

OPEN PRICE ( ) 778.00

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 688

TODAY'S LOW / HIGH ( )766.20 786.60

52 WK LOW / HIGH ( )667.3 1175.2

BSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 19-02 2001

Management Info

Vivek Dhariwal - Chairman Hitesh Windlass - Managing Director

Registered Office

Address 40 / 1,Mohabewala Industrial Area,,
Dehradun,
Uttarakhand-248110

Phone 0135-6608000-30

Email grievance@windlasbiotech.com

Website www.windlasbiotech.com

Registrars Details

MUFG Intime India Pvt Ltd.

C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai

Listing : BSE, NSE

NEWS

29Oct Windlas Biotech informs about analyst
Windlas Biotech has informed that the conference call to discuss financi..

15Sep Intimation Pursuant To Regulation 30
Grant of Units under Windlas Plan 2025 by the Nomination and Remuneratio..

12Aug Windlas Biotech informs about results
Windlas Biotech has informed that it enclosed the Results Presentation f..

12Aug Windlas Biotech informs about outcome
In terms of Regulation 30 and 33 of the Securities & Exchange Board..

30Jun Windlas Biotech informs about analyst
Windlas Biotech has informed that the officials of the Company will be m..

Financials

in Millions

	QTR Sep 25	ANNUAL 25
Net Profit	178	606.49
Gross Profit	235.88	793.94
Operating Profit	322.01	1117.61
Net Sales	2223.98	7598.78

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Alkem Laboratories (BSE) 5689.30 (1.38%)	M.Cap ( in Cr)68024.12
Abbott India (BSE) 28869.35 (0.15%)	M.Cap ( in Cr)61345.35
Glaxosmithkline Phar (BSE) 2543.10 (1.35%)	M.Cap ( in Cr)43081.65
Wockhardt (BSE) 1360.10 (2.16%)	M.Cap ( in Cr)22100.56
RPG Life Sciences (BSE) 2228.80 (1.27%)	M.Cap ( in Cr)3686.22

Shareholding Pattern

	PROMOTERS	61.99%
	MUTUAL FUNDS/UTI	6.39%
	NON-INSTITUTION	25.47%
	FI/BANKS/INSURANCE	0%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
UTI Healthcare Fund...	1.33
ICICI Pru Pharma He...	1.25
ICICI Pru Smallcap ...	0.30
Bandhan BSE Healthc...	0.06
Motilal Oswal BSE H...	0.05
Bandhan Small Cap F...	0.03

attention investors
kyc
ipo
ibt trading
KYC & KRA Status Awareness

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020.

Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

Pay 20% upfront margin of the transaction value to trade in cash market segment.

Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.

Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.
.......... Issued in the interest of Investors

INVESTOR CHARTER

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source: SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

Ratnakar Securities

Smart Quotes

WINDLAS BIOTECH LTD.

Filing complaints on SCORES Easy & quick

RISK DISCLOSURES ON DERIVATIVES